Literature DB >> 33017574

Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction.

Himi Tripathi1, Ahmed Al-Darraji1, Mohamed Abo-Aly1, Hsuan Peng1, Elica Shokri1, Lakshman Chelvarajan1, Renee R Donahue1, Bryana M Levitan1, Erhe Gao2, Gabriela Hernandez1, Andrew J Morris1, Susan S Smyth1, Ahmed Abdel-Latif3.   

Abstract

OBJECTIVE: Acute myocardial infarction (AMI) initiates pathological inflammation which aggravates tissue damage and causes heart failure. Lysophosphatidic acid (LPA), produced by autotaxin (ATX), promotes inflammation and the development of atherosclerosis. The role of ATX/LPA signaling nexus in cardiac inflammation and resulting adverse cardiac remodeling is poorly understood. APPROACH AND
RESULTS: We assessed autotaxin activity and LPA levels in relation to cardiac and systemic inflammation in AMI patients and C57BL/6 (WT) mice. Human and murine peripheral blood and cardiac tissue samples showed elevated levels of ATX activity, LPA, and inflammatory cells following AMI and there was strong correlation between LPA levels and circulating inflammatory cells. In a gain of function model, lipid phosphate phosphatase-3 (LPP3) specific inducible knock out (Mx1-Plpp3Δ) showed higher systemic and cardiac inflammation after AMI compared to littermate controls (Mx1-Plpp3fl/fl); and a corresponding increase in bone marrow progenitor cell count and proliferation. Moreover, in Mx1- Plpp3Δ mice, cardiac functional recovery was reduced with corresponding increases in adverse cardiac remodeling and scar size (as assessed by echocardiography and Masson's Trichrome staining). To examine the effect of ATX/LPA nexus inhibition, we treated WT mice with the specific pharmacological inhibitor, PF8380, twice a day for 7 days post AMI. Inhibition of the ATX/LPA signaling nexus resulted in significant reduction in post-AMI inflammatory response, leading to favorable cardiac functional recovery, reduced scar size and enhanced angiogenesis.
CONCLUSION: ATX/LPA signaling nexus plays an important role in modulating inflammation after AMI and targeting this mechanism represents a novel therapeutic target for patients presenting with acute myocardial injury. Published by Elsevier Ltd.

Entities:  

Keywords:  Autotaxin; Heart failure; Inflammation; Lysophosphatidic acid; Myocardial infarction

Year:  2020        PMID: 33017574      PMCID: PMC7744112          DOI: 10.1016/j.yjmcc.2020.09.011

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  5 in total

Review 1.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

Review 2.  The linkage between inflammation and fibrosis in muscular dystrophies: The axis autotaxin-lysophosphatidic acid as a new therapeutic target?

Authors:  Felipe S Gallardo; Adriana Córdova-Casanova; Enrique Brandan
Journal:  J Cell Commun Signal       Date:  2021-03-10       Impact factor: 5.782

3.  Dexamethasone Alleviates Myocardial Injury in a Rat Model of Acute Myocardial Infarction Supported by Venoarterial Extracorporeal Membrane Oxygenation.

Authors:  Xingdong Cheng; Rongzhi Zhang; Shilin Wei; Jian Huang; Kerong Zhai; Yongnan Li; Bingren Gao
Journal:  Front Public Health       Date:  2022-07-19

4.  Fibrotic Response of Human Trabecular Meshwork Cells to Transforming Growth Factor-Beta 3 and Autotaxin in Aqueous Humor.

Authors:  Mengxuan Liu; Megumi Honjo; Reiko Yamagishi; Nozomi Igarashi; Natsuko Nakamura; Makoto Kurano; Yutaka Yatomi; Koji Igarashi; Makoto Aihara
Journal:  Biomolecules       Date:  2022-09-03

5.  Serum autotaxin as a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy.

Authors:  Takashi Araki; Takahiro Okumura; Hiroaki Hiraiwa; Takashi Mizutani; Yuki Kimura; Shingo Kazama; Naoki Shibata; Hideo Oishi; Tasuku Kuwayama; Toru Kondo; Ryota Morimoto; Mikito Takefuji; Toyoaki Murohara
Journal:  ESC Heart Fail       Date:  2022-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.